The library of libraries is a collection of synthesised antibody libraries. Credit: angellodeco / Shutterstock.com.

Twist Bioscience and Cancer Research UK’s innovation arm Cancer Research Horizons have signed an agreement to license a “library of libraries”.

Twist’s complete library of libraries will be licensed by Cancer Research Horizons for a five-year period.

Twist will obtain a library access fee and will be eligible for annual maintenance fees. It will also receive a portion of the revenue generated from any assets sold or transferred.

Cancer Research Horizons Therapeutic Innovation CEO Hamish Ryder stated: “We’re delighted to partner with Twist Bioscience, an exciting technology platform company that will enhance our antibody discovery capabilities with their highly diverse phage display libraries.

“We look forward to using this technology to accelerate the delivery of high-quality therapeutics and diagnostics to cancer patients, in collaboration with our academic and industrial partners.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

See Also:

The library of libraries is a collection of synthesised antibody libraries, designed using naturally occurring sequences and incorporating innovative structural and developability features to encompass a range of antibody drug targets.

Twist Bioscience CEO and co-founder Emily Leproust stated: “Cancer Research Horizons acts as a conduit between academia and industry, with our collaboration enabling early-stage antibody identification through access to our “library of libraries.”

“With two mission-driven organisations aligning behind innovative technology solutions to improve health to make the world a better place, the opportunity to identify new biotherapeutics offers tremendous hope to those who need it most.”